Core Viewpoint - Abbott has completed the acquisition of Exact Sciences, positioning itself as a leader in the rapidly growing cancer screening and diagnostics market, thereby expanding its ability to serve millions more people [1][2][8]. Group 1: Acquisition Details - The acquisition of Exact Sciences has made it a wholly owned subsidiary of Abbott, with the last trading day for Exact Sciences shares on Nasdaq being March 20, 2026 [2]. - This strategic move is expected to enhance Abbott's operational and commercial capabilities in cancer care, leveraging Exact Sciences' expertise [2][3]. Group 2: Strategic Fit - The transaction allows Abbott to advance its diagnostics offerings, focusing on preventative, predictive, and personalized healthcare solutions in response to the rising global cancer incidence [3]. - Abbott aims to establish leadership in the $60 billion U.S. cancer screening and precision oncology diagnostics market, adding a new growth vertical to its existing high-single-digit growth expectations [3]. Group 3: Product Offerings and Pipeline - Abbott now possesses a comprehensive suite of cancer detection products, including Cologuard®, Oncotype DX®, Oncodetect®, and Cancerguard®, which are designed for early detection and personalized treatment [4][5]. - The company is also enhancing its pipeline with next-generation cancer screening technologies aimed at earlier detection and better disease management [5].